Chimeric Therapeutics is trading 9.09% down now at A$0.01 after another weak session on August 27, 2026.
- No clear company-specific announcement explaining the decline was identified for August 27–28.
- Investor sentiment may still reflect the August 19 announcement that CHM-2101 enrolment and dosing stopped following dose-limiting toxicities; this is prior news, not a confirmed catalyst for this session.
- Broader markets were broadly flat and do not explain the movement.